Table 2 Relationship between GLUT1 mRNA Expression and Clinicopathological Characteristics in Breast Cancer (TCGA data)
From: Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis
Clinicopathologic Characteristics | mRNA Expression | # of Sample(n) | p-Value |
|---|---|---|---|
Sample types | |||
 Normal | ↓ | 114 |  |
 Primary tumor | ↑ | 1097 | <1E-12 |
Patient’s race | |||
 Normal | ↓ | 114 |  |
 Caucasian | ↑ | 748 | 1.62E-12 |
 African-American | ↑ | 179 | 2.44E-10 |
 Asian | ↑ | 61 | 4.02E-10 |
Patient’s age | |||
 Normal | ↓ | 114 |  |
 21–40 Yrs. | ↑ | 97 | 1.36E-10 |
 41–60 Yrs. | ↑ | 505 | <1E-12 |
 61–80 Yrs. | ↑ | 431 | 1.11E-16 |
 81–100 Yrs. | ↑ | 54 | 1.63E-04 |
Individual cancer stages | |||
 Normal | ↓ | 114 |  |
 Stage 1 | ↑ | 183 | 2.61E-14 |
 Stage 2 | ↑ | 615 | 1.62E-12 |
 Stage 3 | ↑ | 247 | 1.62E-12 |
 Stage 4 | ↑ | 20 | 1.10E-01 |
Major subclasses (with TNBC types) | |||
 Normal | ↓ | 114 |  |
 Luminal | ↑ | 556 | 1.62E-12 |
 HER2Pos | ↑ | 37 | 1.94E-03 |
 TNBC-BL1 | ↑ | 13 | 2.97E-04 |
 TNBC-BL2 | ↑ | 11 | 3.24E-03 |
 TNBC-IM | ↑ | 20 | 3.60E-03 |
 TNBC-LAR | ↑ | 8 | 8.89E-02 |
 TNBC-MSL | ↑ | 8 | 8.30E-02 |
 TNBC-M | ↑ | 29 | 8.28E-05 |
 TNBC-UNS | ↑ | 27 | 1.75E-04 |
Tumor histology | |||
 Normal | ↓ | 114 |  |
 IDC | ↑ | 784 | 1.62E-12 |
 ILC | ↑ | 203 | 1.68E-12 |
 Mixed | ↑ | 29 | 2.30E-06 |
 Other | ↑ | 45 | 1.62E-04 |
 Mucinous | ↑ | 17 | 2.90E-03 |
 Metaplastic | ↑ | 9 | 2.67E-01 |
 INOS | ↑ | 1 | N/A |
 Medullary | ↑ | 6 | 2.90E-02 |
Nodal Metastasis status | |||
 Normal | ↓ | 114 |  |
 N0 | ↑ | 516 | 1.62E-12 |
 N1 | ↑ | 362 | 1.62E-12 |
 N2 | ↑ | 120 | 3.98E-08 |
 N3 | ↑ | 77 | 3.53E-09 |
Menopause status | |||
 Normal | ↓ | 114 |  |
 Pre-Menopause | ↑ | 230 | 1.11E-16 |
 Peri-Menopause | ↑ | 37 | 3.00E-03 |
 Post-Menopause | ↑ | 700 | 1.62E-12 |